BioPlus
바이오플러스 · 099430
Health Care Pharmaceuticals · KOSDAQ
Market cap US$226.9M (₩313.1B)
Overview
BioPlus makes hyaluronic acid-based medical products, including dermal fillers (injectable gels used to smooth wrinkles), surgical anti-adhesion barriers, and joint and bladder tissue-repair devices, as well as bio-cosmetics and biopharmaceuticals developed through gene-recombination technology.
Its products are used by medical and aesthetic professionals, and it supplies both domestic and international markets through direct sales and distribution partners. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core revenue is anchored in its filler and tissue-repair device lines, while it is actively expanding into biopharmaceuticals, bio-cosmetics, and biological raw ingredients.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$47.1M
- FY2024US$48.1M
- FY2025US$65.9M
Operating profit
- FY2023US$20.3M
- FY2024US$17.2M
- FY2025US$10.9M
Net income
- FY2023US$19.9M
- FY2024US$12.7M
- FY2025US$14.5M
Key ratios (FY2025)
Why it matters
BioPlus has established an overseas subsidiary in Hainan, China, to build local production facilities and an aesthetic-medicine platform targeting China and neighbouring markets.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?